{"id":4125,"date":"2021-01-20T10:54:23","date_gmt":"2021-01-20T10:54:23","guid":{"rendered":"https:\/\/blog.caixaresearch.org\/?p=4125"},"modified":"2022-10-25T13:29:29","modified_gmt":"2022-10-25T13:29:29","slug":"una-clau-per-curar-les-malalties-cerebrals","status":"publish","type":"post","link":"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/","title":{"rendered":"Una clau per curar les malalties cerebrals"},"content":{"rendered":"<p><strong>***ENGLISH BELOW***<\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-4669\" src=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg\" alt=\"\" width=\"400\" height=\"209\" srcset=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg 800w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1-300x157.jpg 300w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1-768x401.jpg 768w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">A finals del segle <\/span><span style=\"font-weight: 400;\">xix<\/span><span style=\"font-weight: 400;\">, el bacteri\u00f2leg Paul Ehrlich (Premi Nobel de Medicina 1908) va fer un descobriment revolucionari mentre duia a terme un dels seus famosos experiments de tinci\u00f3. Va injectar un tint al torrent sanguini de ratolins que, sorprenentment, va tenyir tots els \u00f2rgans a excepci\u00f3 del cervell i la medul\u00b7la espinal. El que va evitar que el tint entr\u00e9s al cervell va ser una estructura que avui en dia coneixem com a barrera hematoencef\u00e0lica. Formada per una capa de capil\u00b7lars, aquesta barrera nom\u00e9s permet l\u2019entrada al cervell de mol\u00e8cules concretes de la sang.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Alhora que impedeix el pas de pat\u00f2gens i toxines nocives, tamb\u00e9 bloqueja l\u2019entrada de f\u00e0rmacs que podrien curar malalties cerebrals. De fet, m\u00e9s del 98\u00a0% de f\u00e0rmacs candidats no aconsegueixen travessar-la. Per superar-la, un equip d\u2019investigadors de l\u2019<\/span><a href=\"https:\/\/www.irbbarcelona.org\/ca\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Institut de Recerca Biom\u00e8dica<\/span><\/a><span style=\"font-weight: 400;\"> (IRB Barcelona) ha desenvolupat \u201cclaus\u201d min\u00fascules que podrien obrir punts d\u2019entrada a la barrera hametoencef\u00e0lica perqu\u00e8 hi entressin c\u00e0rregues terap\u00e8utiques. Amb el suport de CaixaResearch, acaben de crear una empresa derivada anomenada <\/span><span style=\"font-weight: 400;\">Gate2Brain<\/span><span style=\"font-weight: 400;\">. Estan provant la capacitat de la seva tecnologia per tractar el glioma dif\u00fas intr\u00ednsec de tronc (DIPG), un c\u00e0ncer infantil dur i incurable. Si funcion\u00e9s, aviat es podria fer servir per tractar i curar moltes altres malalties cerebrals. Hem entrevistat la directora executiva de Gate2Brain, Meritxell Teixid\u00f3, per saber m\u00e9s coses d\u2019aquesta tecnologia innovadora.<\/span><\/p>\n<p><iframe loading=\"lazy\" src=\"https:\/\/www.youtube.com\/embed\/9n_Wta1qXVg\" width=\"400\" height=\"500\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p><strong>Per qu\u00e8 el cervell est\u00e0 tan protegit en comparaci\u00f3 amb la resta d\u2019\u00f2rgans?<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">El cervell \u00e9s probablement l\u2019\u00f2rgan m\u00e9s complex i essencial, per\u00f2 tamb\u00e9 el m\u00e9s vulnerable. Per aix\u00f2, els nostres organismes han desenvolupat la barrera hematoencef\u00e0lica per protegir-lo. Per\u00f2 aquesta barrera protectora tamb\u00e9 fa molt dif\u00edcil tractar les malalties cerebrals.<\/span><\/p>\n<p><strong>Com ajudar\u00e0 Gate2Brain els f\u00e0rmacs a travessar la barrera hematoencef\u00e0lica?<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">La barrera hematoencef\u00e0lica \u00e9s com un mur que evita que les toxines de la sang entrin al cervell. Aquest mur t\u00e9 algunes portes a trav\u00e9s de les quals entren nutrients i s\u2019expulsen residus.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">La tecnologia Gate2Brain es basa en mol\u00e8cules petites conegudes com a p\u00e8ptids, que s\u00f3n capaces de travessar la barrera mitjan\u00e7ant mecanismes diversos. El nostre objectiu \u00e9s fixar agents terap\u00e8utics als p\u00e8ptids perqu\u00e8 actu\u00efn com una clau, obrin aquestes portes i transportin f\u00e0rmacs a parts del cervell a les quals no podrien arribar tots sols.\u00a0<\/span><\/p>\n<p><strong>Per qu\u00e8 vau escollir els p\u00e8ptids com a clau per travessar la barrera hematoencef\u00e0lica?<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">Ens vam inspirar en la natura, especialment en els animals verinosos. Trobem p\u00e8ptids en molts verins que tenen la capacitat d\u2019arribar al cervell. Quan els vam estudiar, vam descobrir quina part era la responsable d\u2019aquesta capacitat i aix\u00ed vam desenvolupar les nostres \u201cclaus\u201d.<\/span><\/p>\n<p><strong>Qui es beneficiar\u00e0 de la tecnologia Gate2Brain?<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">Malgrat que ens pugui sorprendre, una de cada quatre persones haur\u00e0 de ser tractada d\u2019una malaltia cerebral en algun moment de la vida. Aix\u00f2 inclou la malaltia d\u2019Alzheimer, la de Parkinson, l\u2019esquizofr\u00e8nia i moltes malalties minorit\u00e0ries i tumors cerebrals. Aix\u00ed que, de fet, totes aquelles persones que podrien ser tractades amb un f\u00e0rmac que no \u00e9s capa\u00e7 de travessar la barrera hematoencef\u00e0lica es beneficiarien de la nostra tecnologia.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Ara estem provant aquesta tecnologia en una malaltia espec\u00edfica anomenada glioma dif\u00fas intr\u00ednsec de tronc (DIPG), un c\u00e0ncer minoritari i incurable que afecta nens. En aquest cas, l\u2019agent quimioterap\u00e8utic necessita una ajuda per arribar al cervell.\u00a0<\/span><\/p>\n<p><strong>Com ha ajudat CaixaResearch el vostre projecte?<\/strong><\/p>\n<p><span style=\"font-weight: 400;\">CaixaResearch ens ha ajudat a fer el salt del laboratori a la creaci\u00f3 de l\u2019empresa, no nom\u00e9s pel que fa al finan\u00e7ament, sin\u00f3 tamb\u00e9 en formaci\u00f3 i mentoria. Gr\u00e0cies a aix\u00f2 hem engegat una empresa derivada. D\u2019ara endavant esperem poder desenvolupar la nostra tecnologia per curar tant nens com adults que pateixin malalties cerebrals.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>***********<\/p>\n<h1><b>A key to cure brain diseases<\/b><\/h1>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-5810\" src=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Gate2Brain_ENG-300x157.jpg\" alt=\"\" width=\"400\" height=\"209\" srcset=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Gate2Brain_ENG-300x157.jpg 300w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Gate2Brain_ENG-1024x535.jpg 1024w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Gate2Brain_ENG-768x401.jpg 768w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Gate2Brain_ENG-1536x802.jpg 1536w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Gate2Brain_ENG-2048x1070.jpg 2048w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">In the late 19th century, the bacteriologist Paul Ehrlich (Nobel Prize in Medicine 1908) made a revolutionary discovery while conducting one of his famous staining experiments. He injected a dye into the bloodstream of mice that surprisingly stained all organs except the brain and spinal cord. What prevented the dye from entering the brain was a structure now known as the blood-brain barrier. Formed by a layer of capillaries, this barrier allows only select molecules in our blood to enter the brain.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">While keeping out harmful pathogens and toxins, it also blocks the entry of drugs that can potentially cure brain diseases. In fact, more than 98% of drug candidates fail to cross it. To overcome this, a team of researchers at the <\/span><a href=\"https:\/\/www.irbbarcelona.org\/en\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Institute for Research in Biomedicine<\/span><\/a><span style=\"font-weight: 400;\"> (IRB Barcelona) has developed tiny \u201ckeys\u201d that can unlock entry points on the blood-brain barrier to let in therapeutic cargoes. With the support of a CaixaImpulse, they recently created a spinoff called <\/span><span style=\"font-weight: 400;\">Gate2Brain<\/span><span style=\"font-weight: 400;\">. They are currently testing the ability of their technology to treat diffuse intrinsic pontine glioma (DIPG)\u2014a devastating and incurable childhood cancer. If successful, it could soon be used to treat and even cure numerous other brain diseases. We recently interviewed Gate2Brain CEO Meritxell Teixid\u00f3 to learn more about this innovative technology.<\/span><\/p>\n<p><strong><i>Why is the brain so highly protected compared to other organs?<\/i><\/strong><\/p>\n<p><span style=\"font-weight: 400;\">The brain is probably our most complex and essential organ, but it is also the most vulnerable to damage. That\u2019s why our bodies have evolved the blood-brain barrier to protect it. But this protective barrier also makes it very difficult to treat brain diseases.<\/span><\/p>\n<p><strong><i>How will Gate2Brain help drugs to cross the blood-brain barrier?<\/i><\/strong><\/p>\n<p><span style=\"font-weight: 400;\">The blood-brain barrier is like a brick wall that stops toxins in the blood from entering the brain. This wall has certain gates through which nutrients pass and waste is removed.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Gate2Brain technology is based on small molecules known as peptides, which are capable of crossing this barrier through various mechanisms. Our objective is to bind therapeutic agents to the peptides so that they act as a &#8216;key&#8217;, open these gates and transport drugs to parts of the brain that they cannot reach by themselves.\u00a0<\/span><\/p>\n<p><strong><i>Why did you choose peptides as the key to crossing the blood-brain barrier?<\/i><\/strong><\/p>\n<p><span style=\"font-weight: 400;\">We were inspired by nature, or more specifically, by venomous animals. Peptides are found in many venoms that have the ability to reach the brain. By studying them, we worked out which part was responsible for that ability and thus developed our &#8216;keys&#8217;.<\/span><\/p>\n<p><strong><i>Who will benefit from Gate2Brain technology?<\/i><\/strong><\/p>\n<p><span style=\"font-weight: 400;\">Shockingly, one in four of us will need to be treated for a brain disease in our lifetime. This includes conditions such as Alzheimer&#8217;s, Parkinson&#8217;s, schizophrenia, as well as numerous rare diseases and brain tumors. So in reality, all the people for whom there is a drug candidate that cannot reach the brain are the ones who will benefit from our technology.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">We are currently testing this technology on a specific illness called diffuse intrinsic pontine glioma (DIPG)\u2014a rare and incurable brain cancer that affects children. In this case, the chemotherapeutic agent really needs a push to reach the brain.\u00a0<\/span><\/p>\n<p><strong><i>How has CaixaImpulse helped your project?<\/i><\/strong><\/p>\n<p><span style=\"font-weight: 400;\">CaixaImpulse has helped us to take that leap from the laboratory to the creation of the company, not only in financing, but also in training and mentoring. As a result, we have now launched as a spinoff. From here we hope to further develop our technology in order to cure children and adults alike who suffer from a variety of brain diseases.\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>***ENGLISH BELOW***<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-4669\" src=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg\" alt=\"\" width=\"400\" height=\"209\" srcset=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg 800w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1-300x157.jpg 300w, https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1-768x401.jpg 768w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/p>\n<p>A finals del segle xix, el bacteri\u00f2leg Paul Ehrlich (Premi Nobel de Medicina 1908) va fer un descobriment revolucionari mentre duia a terme un dels seus famosos experiments de tinci\u00f3. Va injectar un tint al torrent sanguini de ratolins que, sorprenentment, va tenyir tots els \u00f2rgans a excepci\u00f3 del cervell i la medul\u00b7la espinal. El que va evitar que el tint entr\u00e9s al cervell va ser una estructura que avui en dia coneixem com a barrera hematoencef\u00e0lica. Formada per una capa de capil\u00b7lars, aquesta barrera nom\u00e9s permet l\u2019entrada al cervell de mol\u00e8cules concretes de la sang.<\/p>\n<p>Alhora que impedeix el pas de pat\u00f2gens i toxines nocives, tamb\u00e9 bloqueja l\u2019entrada de f\u00e0rmacs que podrien curar malalties cerebrals.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[519],"tags":[],"class_list":["post-4125","post","type-post","status-publish","format-standard","hentry","category-investigacio"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Una clau per curar les malalties cerebrals - Blog CaixaCi\u00e8ncia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Una clau per curar les malalties cerebrals - Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"og:description\" content=\"***ENGLISH BELOW*** A finals del segle xix, el bacteri\u00f2leg Paul Ehrlich (Premi Nobel de Medicina 1908) va fer un descobriment revolucionari mentre duia a terme un dels seus famosos experiments de tinci\u00f3. Va injectar un tint al torrent sanguini de ratolins que, sorprenentment, va tenyir tots els \u00f2rgans a excepci\u00f3 del cervell i la medul\u00b7la espinal. El que va evitar que el tint entr\u00e9s al cervell va ser una estructura que avui en dia coneixem com a barrera hematoencef\u00e0lica. Formada per una capa de capil\u00b7lars, aquesta barrera nom\u00e9s permet l\u2019entrada al cervell de mol\u00e8cules concretes de la sang. Alhora que impedeix el pas de pat\u00f2gens i toxines nocives, tamb\u00e9 bloqueja l\u2019entrada de f\u00e0rmacs que podrien curar malalties cerebrals.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-20T10:54:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-25T13:29:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg\" \/>\n<meta name=\"author\" content=\"Ubikmedia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ubikmedia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/\",\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/\",\"name\":\"Una clau per curar les malalties cerebrals - Blog CaixaCi\u00e8ncia\",\"isPartOf\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg\",\"datePublished\":\"2021-01-20T10:54:23+00:00\",\"dateModified\":\"2022-10-25T13:29:29+00:00\",\"author\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/#primaryimage\",\"url\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg\",\"contentUrl\":\"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\",\"url\":\"https:\/\/blog.caixaresearch.org\/\",\"name\":\"Blog CaixaCi\u00e8ncia\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.caixaresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca\",\"name\":\"Ubikmedia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g\",\"caption\":\"Ubikmedia\"},\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/author\/ubikmedia\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Una clau per curar les malalties cerebrals - Blog CaixaCi\u00e8ncia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/","og_locale":"ca_ES","og_type":"article","og_title":"Una clau per curar les malalties cerebrals - Blog CaixaCi\u00e8ncia","og_description":"***ENGLISH BELOW*** A finals del segle xix, el bacteri\u00f2leg Paul Ehrlich (Premi Nobel de Medicina 1908) va fer un descobriment revolucionari mentre duia a terme un dels seus famosos experiments de tinci\u00f3. Va injectar un tint al torrent sanguini de ratolins que, sorprenentment, va tenyir tots els \u00f2rgans a excepci\u00f3 del cervell i la medul\u00b7la espinal. El que va evitar que el tint entr\u00e9s al cervell va ser una estructura que avui en dia coneixem com a barrera hematoencef\u00e0lica. Formada per una capa de capil\u00b7lars, aquesta barrera nom\u00e9s permet l\u2019entrada al cervell de mol\u00e8cules concretes de la sang. Alhora que impedeix el pas de pat\u00f2gens i toxines nocives, tamb\u00e9 bloqueja l\u2019entrada de f\u00e0rmacs que podrien curar malalties cerebrals.","og_url":"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/","og_site_name":"Blog CaixaCi\u00e8ncia","article_published_time":"2021-01-20T10:54:23+00:00","article_modified_time":"2022-10-25T13:29:29+00:00","og_image":[{"url":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg","type":"","width":"","height":""}],"author":"Ubikmedia","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Ubikmedia","Temps estimat de lectura":"6 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/","url":"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/","name":"Una clau per curar les malalties cerebrals - Blog CaixaCi\u00e8ncia","isPartOf":{"@id":"https:\/\/blog.caixaresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/#primaryimage"},"image":{"@id":"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg","datePublished":"2021-01-20T10:54:23+00:00","dateModified":"2022-10-25T13:29:29+00:00","author":{"@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/ca\/una-clau-per-curar-les-malalties-cerebrals\/#primaryimage","url":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg","contentUrl":"https:\/\/blog.caixaresearch.org\/wp-content\/uploads\/2021\/01\/Card_Gate2Brain_CAT-1.jpg"},{"@type":"WebSite","@id":"https:\/\/blog.caixaresearch.org\/#website","url":"https:\/\/blog.caixaresearch.org\/","name":"Blog CaixaCi\u00e8ncia","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.caixaresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca","name":"Ubikmedia","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g","caption":"Ubikmedia"},"url":"https:\/\/blog.caixaresearch.org\/ca\/author\/ubikmedia\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/4125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/comments?post=4125"}],"version-history":[{"count":7,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/4125\/revisions"}],"predecessor-version":[{"id":5812,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/4125\/revisions\/5812"}],"wp:attachment":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/media?parent=4125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/categories?post=4125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/tags?post=4125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}